Ginkgo Bioworks Holdings, Inc. Warrants, each whole warrant exercisable to purchase one-fortieth (1/40th) of a share of Class A Common Stock at an exercise price of $460.00 per share
DNA.WS
DNA.WS was delisted on the 3rd of September, 2024.
49 hedge funds and large institutions have $177M invested in Ginkgo Bioworks Holdings, Inc. Warrants, each whole warrant exercisable to purchase one-fortieth (1/40th) of a share of Class A Common Stock at an exercise price of $460.00 per share in 2022 Q3 according to their latest regulatory filings, with 5 funds opening new positions, 2 increasing their positions, 12 reducing their positions, and 5 closing their positions.
3,644% more capital invested
Capital invested by funds: $4.73M → $177M (+$172M)
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
0% more funds holding
Funds holding: 49 → 49 (0)
0% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 5
83% less repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 12
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ICM
Ionic Capital Management
New York
|
+$54.2K |
| 2 |
LOAMU
Lombard Odier Asset Management (USA)
New York
|
+$17.1K |
| 3 |
TSS
Two Sigma Securities
New York
|
+$14.1K |
| 4 |
FLC
Fifth Lane Capital
Austin,
Texas
|
+$10K |
| 5 |
Edgewood Management
Greenwich,
Connecticut
|
+$6.83K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GC
Guggenheim Capital
Chicago,
Illinois
|
-$23.8M |
| 2 |
M
Murchinson
Toronto,
Ontario, Canada
|
-$71.2K |
| 3 |
CH
CVI Holdings
Wilmington,
Delaware
|
-$60.9K |
| 4 |
TCA
Taconic Capital Advisors
New York
|
-$52.5K |
| 5 |
WAM
Weiss Asset Management
Boston,
Massachusetts
|
-$43.6K |
DNA.WS Hedge Fund Activity: Q3 2022 in Review
49 of the 5,828 institutional investors tracked by Wall St. Rank reported a position in Ginkgo Bioworks Holdings, Inc. Warrants, each whole warrant exercisable to purchase one-fortieth (1/40th) of a share of Class A Common Stock at an exercise price of $460.00 per share (DNA.WS) for Q3 2022, worth a combined $177M — up 3,644% from $4.73M a quarter earlier.
Fund positioning in DNA.WS was balanced in Q3 2022: 5 funds opened new positions, 5 closed out, 2 added to existing stakes and 12 trimmed.
The largest buyer was Ionic Capital Management, adding an estimated $54.2K. The largest seller was Guggenheim Capital, cutting an estimated $23.8M.
- 49 institutional investors held Ginkgo Bioworks Holdings, Inc. Warrants, each whole warrant exercisable to purchase one-fortieth (1/40th) of a share of Class A Common Stock at an exercise price of $460.00 per share (DNA.WS) as of Q3 2022, unchanged from Q2 2022.
- Funds reported $177M of Ginkgo Bioworks Holdings, Inc. Warrants, each whole warrant exercisable to purchase one-fortieth (1/40th) of a share of Class A Common Stock at an exercise price of $460.00 per share stock for Q3 2022, up 3,644% quarter-over-quarter.
- 5 funds opened new Ginkgo Bioworks Holdings, Inc. Warrants, each whole warrant exercisable to purchase one-fortieth (1/40th) of a share of Class A Common Stock at an exercise price of $460.00 per share positions in Q3 2022 and 5 closed out, a net change of 0 holders.
- The largest Ginkgo Bioworks Holdings, Inc. Warrants, each whole warrant exercisable to purchase one-fortieth (1/40th) of a share of Class A Common Stock at an exercise price of $460.00 per share buyer in Q3 2022 was Ionic Capital Management, an estimated $54.2K added.
- The largest Ginkgo Bioworks Holdings, Inc. Warrants, each whole warrant exercisable to purchase one-fortieth (1/40th) of a share of Class A Common Stock at an exercise price of $460.00 per share seller in Q3 2022 was Guggenheim Capital, an estimated $23.8M sold.
Based on aggregated 13F filings for Q3 2022.